Skip to main content
Premium Trial:

Request an Annual Quote

SBI, Quest Team to Apply Pharmacogenomics to Drug And Healthcare Research

Premium

SAN DIEGO--Quest Diagnostics of Teterboro, N.J., and Structural Bioinformatics here announced a strategic alliance regarding the application of structural pharmacogenomics to clinical testing and pharmaceutical research. Structural Bioinformatics will extend existing and generate new proprietary target-specific structural variant database modules for a number of therapeutic targets based on Quest's clinical sequence databases. These modules will permit modeling of structurally variant proteins to facilitate design and identification of best-in-class drug compounds, according to the two companies. The databases will be jointly offered under the QSVdBase name by both companies for licensing to the pharmaceutical industry within the year. Patrick Hess, director of biotechnology affairs at Quest's Nichols Institute, said, "The structural variant databases generated from our genotyping databases should provide a fertile new source of information helpful in the design of new antiviral compounds using the structure-based drug discovery approach pioneered by Structural Bioinformatics."

Filed under

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.